Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3787 PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,

#3525 Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated lanreotide autogel/depot (LAN) in metastatic somatostatin receptor (SSTR)-positive typical and atypical (TC and AC) BP NETs.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, prognostic factor, spinet, typical/atypical carcinoid,

#3518 Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated LAN in metastatic somatostatin receptor (SSTR)-positive typical and atypical carcinoid (TC and AC) BP-NETs.

Conference:

Presenting Author: Capdevila J

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, spinet, tumor growth rate, typical/atypical carcinoid,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Chan D, Ferone D, Segelov E, Albertelli M, Singh S,

Keywords: Escalated dose, octreotide, lanreotide, SSA,